ReviewCellular & molecular biology letters2022
Osteoporosis pathogenesis and treatment: existing and emerging avenues.
Review in Cellular & molecular biology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 5 syntheses or guidelines pooled it, 201 citations in OpenAlex.
- Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials.Clinical and experimental medicine · 2026Pooled it
- Effects of kaempferol on bone loss in animal models of osteoporosis: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Efficacy of acupuncture for primary osteoporosis: a systematic review and meta-analysis of randomized controlled trials.Journal of orthopaedic surgery and research · 2025Pooled it
- B vitamins and bone health: a meta-analysis with trial sequential analysis of randomized controlled trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Pooled it
- Osteoporosis treatment using stem cell-derived exosomes: a systematic review and meta-analysis of preclinical studies.Stem cell research & therapy · 2023Pooled it
- Trial
- A motion-activated skeletal "Pacemaker" for systemic bone remodeling via oral piezoelectric microspheres.Bioactive materials · 2026Article
- Cellular senescence and the SASP in skeletal ageing: convergent mechanisms of progressive bone loss in osteoporosis.Biogerontology · 2026Review
- Xylosyltransferase-I serum activity is a promising biomarker for postmenopausal osteoporosis.Scientific reports · 2026Article
- Bone organic matrix quality indices associate with fragility fracture occurrence independently of bone mineral density values.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Apoptosis of Mdm2-deficient osteocytes enhances osteogenesis through TRPM8-enriched apoptotic vesicles.Bone research · 2026Article
- Role of the Antioxidant Lycopene in Bone Health: Emphasis on the RANKL/RANK/OPG Signaling Pathway.Food science & nutrition · 2026Review
- Tri-modal nanocatalytic microenvironment regulations for macrophage reprogramming and osteoporotic fracture healing promotion.Materials today. Bio · 2026Article
- The Role of Short-Chain Fatty Acids and Derived Metabolites in Osteoporosis.Current osteoporosis reports · 2026Review
- Inhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass.Bone research · 2026Article
- Platelet-derived biomaterials in osteoporosis: mechanisms, evidence and translational prospects.Journal of biological engineering · 2026Review
- 24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore.Journal of bone and mineral metabolism · 2026Article
- Hybrid extracellular vesicles for targeted delivery of therapeutic cargoes to combat osteoporotic bone loss.Cell biomaterials · 2026Article
- M-CSF priming enhances the efficiency and reproducibility of hiPSC-derived osteoclast differentiation and pharmacological responsiveness to anti-resorptive agents.Scientific reports · 2026Article
- MiR-642a-3p increases the risk of postmenopausal osteoporosis and fractures by targeting INO80.Hereditas · 2026Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Osteoporotic fractures lead to increased disability and mortality in the elderly population. With the rapid increase in the aging population around the globe, more effective treatments for osteoporosis and osteoporotic fractures are urgently required. The underlying molecular mechanisms of osteoporosis are believed to be due to the increased activity of osteoclasts, decreased activity of osteoblasts, or both, which leads to an imbalance in the bone remodeling process with accelerated bone resorption and attenuated bone formation. Currently, the available clinical treatments for osteoporosis have mostly focused on factors influencing bone remodeling; however, they have their own limitations and side effects. Recently, cytokine immunotherapy, gene therapy, and stem cell therapy have become new approaches for the treatment of various diseases. This article reviews the latest research on bone remodeling mechanisms, as well as how this underpins current and potential novel treatments for osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.